Serhat Gumrukcu Net Worth

The estimated Net Worth of Serhat Gumrukcu is at least $10.6 Million dollars as of 18 May 2022. Serhat Gumrukcu owns over 253,493 units of Enochian Biosciences Inc stock worth over $8,591,141 and over the last 2 years Serhat sold ENOB stock worth over $2,027,944.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Serhat Gumrukcu ENOB stock SEC Form 4 insiders trading

Serhat has made over 1 trades of the Enochian Biosciences Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Serhat sold 253,493 units of ENOB stock worth $2,027,944 on 18 May 2022.

The largest trade Serhat's ever made was selling 253,493 units of Enochian Biosciences Inc stock on 18 May 2022 worth over $2,027,944. On average, Serhat trades about 253,493 units every 0 days since 2022. As of 18 May 2022 Serhat still owns at least 12,273,059 units of Enochian Biosciences Inc stock.

You can see the complete history of Serhat Gumrukcu stock trades at the bottom of the page.

What's Serhat Gumrukcu's mailing address?

Serhat's mailing address filed with the SEC is C/O ENOCHIAN BIOSCIENCES INC., 2080 CENTURY CITY EAST, SUITE 906, LOS ANGELES, CA, 90067.

Insiders trading at Enochian Biosciences Inc

Over the last 7 years, insiders at Enochian Biosciences Inc have traded over $2,106,789 worth of Enochian Biosciences Inc stock and bought 552,919 units worth $3,888,612 . The most active insiders traders include Gregg H Alton, Rene Sindlev, and Serhat Gumrukcu. On average, Enochian Biosciences Inc executives and independent directors trade stock every 91 days with the average trade being worth of $35,881. The most recent stock trade was executed by Serhat Gumrukcu on 18 May 2022, trading 253,493 units of ENOB stock currently worth $2,027,944.

What does Enochian Biosciences Inc do?

enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and cancer. the company’s lead candidate eno-1001 (pre-ind) is a potentially sterilizing cure for hiv/aids. eno-2001 is an hiv vaccine in preclinical stage, and its additional compounds eno-4001 (phase three asset), eno-4002, eno-5001, and eno-3001 are in discovery stages for prevention relapse in colon cancer patients. enochian biosciences is headquartered in los angeles, california.

Complete history of Serhat Gumrukcu stock trades at Enochian Biosciences Inc

Enochian Biosciences Inc executives and stock owners

Enochian Biosciences Inc executives and other stock owners filed with the SEC include:

• Mark Dybul,
  Executive Vice Chairman of the Board, Principal Executive Officer
• Luisa Puche,
  Chief Financial Officer
• Dr. Mark R. Dybul M.D.,
  Chief Exec. Officer & Director
• Luisa Puche,
  Chief Financial Officer
• Evelyn D'An,
  Independent Director
• James Sapirstein,
  Independent Director
• Carl Sandler,
  Independent Director
• Henrik Gronfeldt-Sorensen,
  Director
• Rene Sindlev,
  Independent Chairman of the Board
• Gregg Alton,
  Independent Director
• Carol Brosgart,
  Independent Director
• Dr. François Binette M.Sc., Ph.D.,
  Exec. VP for R&D
• Greg Duczynski Ph.D.,
  Sr. VP for Clinical Operations
• Dr. Serhat Gümrükcü,
  Co-Founder & Inventor
• Tung Nguyen,
  Head of Molecular Biology
• Dr. Wenshi Wang,
  Sr. VP of Operations
• Dr. Serhat Gümrükcü,
  Co-Founder & Inventor
• Francois Binette,
  Executive VP for R&D
• Jayne Mc Nicol,
  Director
• Eric Jean Marie Leire,,
  
• Carl Forest Sandler,
  
• Serhat Gumrukcu,
  10% owner
• Anderson Wittekind William,
  
• Science Llc Weird,